Trading Halt
Filed with ASX · · 3 pages · English
On 6ix: 6ix.com/news/trading-halt-582
Trading in the securities of Cyclopharm Limited (‘CYC’) will be halted at the request of CYC, pending the release of an announcement by CYC. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of: • the commencement of normal trading on Wednesday, 4 February 2026; or • the release of the announcement to the market. CYC’s request for a trading halt is attached
In the deck
Earlier from Cyclopharm
- COPD Study Leveraging Technegas and AI-Driven Lung Analysis
- Technegas Recognised in Updated Clinical Guideline
- Insurer Indemnifies Cyclopharm
- Stanford Children's Health to Implement Technegas
- Colombia Approval Marks 67th Country for Technegas
Later from Cyclopharm
- CYC Unaudited Trading Update - Preliminary FY2025 Results
- Cyclopharm Successfully Completes A$14 million Placement
- Cyclopharm Capital Raising Investor Presentation
- Technegas Approved at the US National Institutes of Health
- Technegas US Footprint Expanding Across Four Regions
Follow Cyclopharm into a list and get an email when it puts out news.
Follow Cyclopharm